In a high level meeting on antibiotic resistance all 193 united nations members are set to sign a declaration agreeing to combat whats been termed as ‘the biggest threat to modern medicine.’
Jeffrey LeJeune, a professor and head of the food animal research program at Ohio State University said “It’s ironic that such a small thing is causing such an enormous public threat, but it is a global health threat that needs a global response.”
To put this into perspective more than 700,000 people die each year due to drug resistant infections, but since there is no global monitoring system the number could be much higher.
Stephen OHara, OptiBiotix Health Plc CEO (LON:OPTI) said: ‘This is good news in the fight against antibiotic resistant bacteria which kill more than 700,000 people each year and is seen as a global threat to how we practice modern medicine. OptiBiotix announced the filing of patents in May 2016 which protects advances made in its skin division in identifying microbial proteins which have the potential to prevent resistant bacteria from causing infections. These proteins prevent skin damage, stop pathogenic bacteria from growing, and most importantly prevent them from reattaching, reducing the risk of reinfection from resistant bacteria. The mechanism of action is different from current treatments which may kill bacteria but then allow reattachment and is an exciting advance on current therapies. We would hope to commence humans studies on this new technology at the start of 2017.”
